Simple Transanal Local Excision，Transanal Local Excision Following Radiotherapy Versus Total Mesorectum Excision for the Treatment of the Ultra-low T2N0M0 Rectal Cancer

• Sponsor: The First Affiliated Hospital with Nanjing Medical University (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT04098471
• Collaborator: (none)
• Enrollment: 300
• Arms: 3
• Anticipated Duration (Months): 84

Study Details

Study Description

Brief Summary

A randomized controlled clinical trial to compare the short and long term outcomes of simple transanal local excision，transanal local excision following radiotherapy or total mesorectal excision for the treatment of Rectal Cancer

Condition or Disease	Intervention/Treatment	Phase
Rectal Cancer	Procedure: transanal local excision following radiotherapy	N/A

Detailed Description

Rectal cancer is one of the most common malignancy worldwide. Currently, surgery is the main treatment for stage I rectal cancer, which has good therapeutic effect. For ultra-low rectal cancer, transanal local excision (TLE) has many advantages over total mesorectal excision (TME), such as less trauma, shorter hospitalization time, lower incidence of complications, protection of sexual function and protection of anal function. At present, transanal local excision has become the recommended operation for the T1N0M0 rectal cancer. However, the risk of lymph node metastasis still occurs in stage I tumors, especially in stage T2 tumors, the lymph node metastasis rate can reach 12% - 29% according to the literature. Salvage TME or chemoradiotherapy should be considered for the presence of positive margin of incision, lymphatic/vascular invasion and poor histological differentiation after transanal local excision. At present, the investigators have consulted a large number of literatures and found that TEM is still lack of sufficient evidence in the treatment of T2N0M0 ultra-low rectal cancer. Some studies believed that local excision combined with adjuvant therapy is safe and reliable, but the evidence is not enough. For ultra-low T2N0M0 rectal cancer, more studies need to be carried out to provide guidance for clinical treatment.

In this study, eligible patients will be randomly allocated to operative operation for rectal cancer either by simple TLE，TLE following radiotherapy or TME. 5-years disease free survival rate, 5-years overall survival rate，local recurrence rate and postoperative quality of life will be recorded. Patients will be followed up every 3 months for 2 year, every 6 months for 3 years postoperatively to study the long term effects.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 300 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Care Provider)
• Primary Purpose: Treatment
• Official Title: A Randomized Controlled Clinical Trial to Investigate the Effects of Transanal Local Excision Following Radiotherapy for the Treatment of Ultra-low T2N0M0 Rectal Cancer
• Anticipated Study Start Date: Dec 1, 2019
• Anticipated Primary Completion Date: Dec 1, 2026
• Anticipated Study Completion Date: Dec 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: single transanal loca excision	Procedure: transanal local excision following radiotherapy; transanal local excision following radiotherapy
Experimental: transanal local excision following radiotherapy	Procedure: transanal local excision following radiotherapy; transanal local excision following radiotherapy
Experimental: total mesorectal excision	Procedure: transanal local excision following radiotherapy; transanal local excision following radiotherapy

Outcome Measures

Primary Outcome Measures

1. 5-years disease free survival rate [5 years]

Secondary Outcome Measures

1. 5-years overall survival rate [5 years]

2. local recurrance rate [5 years]

3. operative time [1 day]

4. hospitalization time [15 days]

5. postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire [5 years]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Preoperative pathology confirmed adenocarcinoma.

2. Preoperative MRI or digital examination of tectum confirmed that the distances from the lower edge of the tumors to the anus were less than 5 cm.

3. The mass is not fixed.

4. Preoperative MRI and rectal EUS indicated that the tumor only invaded muscular layer (T2).

5. No suspicious lymphatic metastasis or distant metastasis was found on preoperative high-resolution CT and MRI.

6. American Society of Anesthesiologists(ASA) grade I-III.

7. Informed consent.

8. No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.

Exclusion Criteria:

1. Age<18, or>75.

2. Have other cancer history.

3. The pathology of rectal tumors is non-adenocarcinoma.

4. Multiple primary colorectal tumors.

5. Preoperative CT and MR showed that lymphatic metastasis and distant metastasis could be positive.

6. Pregnant or lactating women.

7. Patients with severe mental disorders.

8. ASA score > 3.

9. Receive other cancer treatments (radiotherapy, chemotherapy).

10. Complication with other intestinal diseases (FAP, HNPCC, active ulcerative colitis or Crohn's disease).

11. The general situation is poor and there are other uncontrollable diseases.

12. Preoperative tumor stage was not T2N0M0.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• The First Affiliated Hospital with Nanjing Medical University

Investigators

• Study Director: Yueming Sun, PhD, The First Affiliated Hospital with Nanjing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: The First Affiliated Hospital with Nanjing Medical University
• ClinicalTrials.gov Identifier: NCT04098471
• Other Study ID Numbers: CRSYM201909
• First Posted: Sep 23, 2019
• Last Update Posted: Sep 23, 2019
• Last Verified: Sep 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by The First Affiliated Hospital with Nanjing Medical University: transanal local excision; T2N0M0
• Additional relevant MeSH terms: Rectal Neoplasms

Study Results

No Results Posted as of Sep 23, 2019